Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 33.3%Low 2 · 66.7%Moderate 0 · 0%High 0 · 0%

Buprenorphine vs alpha2‐adrenergic agonists

Number experiencing adverse effects · Adults or adolescents with opioid dependence

It is very uncertain whether buprenorphine changes number experiencing adverse effects compared with alpha2‐adrenergic agonists (very low certainty).

1 finding from 1 review

Buprenorphine for managing opioid withdrawal 2017 · Cochrane Headline outcomes only
RR 0.93 [0.7, 1.26]
3 studies · 493 participants
Very low

Buprenorphine vs alpha2‐adrenergic agonists

Number with treatment stopped due to adverse effects · Adults or adolescents with opioid dependence

Buprenorphine showed no clear difference in number with treatment stopped due to adverse effects compared with alpha2‐adrenergic agonists (low certainty).

1 finding from 1 review

Buprenorphine for managing opioid withdrawal 2017 · Cochrane Headline outcomes only
RR 0.2 [0.04, 1.15]
3 studies · 134 participants
Low

Full opioid agonists vs different full opioid agonists or partial opioid agonists (methadone versus buprenorphine)

Adverse effects · pharmaceutical opioid dependent people

Full opioid agonists showed no clear difference in adverse effects compared with different full opioid agonists or partial opioid agonists (methadone… (low certainty).

1 finding from 1 review

Opioid agonist treatment for people who are dependent on pharmaceutical opioids 2022 · Cochrane Headline outcomes only
RR 0.45 [0.09, 2.41]
3 studies · 206 participants
Low